Elevated serum EphA2 independently determined reduced eGFR (<60 mL/min/1.73m2), correlated with histological severity, and significantly decreased after steroid therapy in IgA nephropathy.
Does integrating metabolite signatures with clinical variables improve diagnostic performance for advanced CKM stages in patients with CKM syndrome?
Integrating specific lipid-centric metabolite signatures with clinical variables enhances the diagnostic performance for identifying advanced stages of cardiovascular-kidney-metabolic syndrome.
Absolute Event Rate: 0% vs 0%
Methods: Methods: Circulating EphA2 levels were measured by enzyme-linked immunosorbent assay (ELISA) in 102 participants with biopsy-proven IgA nephropathy who underwent tonsillectomy followed by steroid pulse therapy.Blood samples were obtained before renal biopsy and immediately prior to the third course of steroid pulse therapy.Detailed clinical data and pathological data, including demographic characteristics, comorbidities, and Oxford MEST-C scores, were analyzed to assess the association between serum EphA2 levels and histological severity.Results: Baseline EphA2 levels were positively correlated with histological severity, particularly the degree of global glomerulosclerosis, tubular atrophy, and interstitial fibrosis, and were inversely correlated with estimated glomerular filtration rate (eGFR) prior to biopsy.Multivariate logistic regression analysis revealed that elevated EphA2 was an independent determinant of reduced eGFR (<60 mL/min/1.73m 2 ), even after adjustment for age, sex, and proteinuria.Although eGFR remained largely unchanged after treatment, both proteinuria and serum EphA2 levels significantly decreased following steroid pulse therapy, indicating a favorable treatment response.Conclusion: Serum EphA2 demonstrates a strong correlation with both renal function and histological severity and further reflects treatment response in individuals with IgA nephropathy.These findings suggest that EphA2 may serve as a novel biomarker for assessing both kidney impairment and therapeutic efficacy in this population.I have no potential conflict of interest to disclose.I did not use generative AI and AI-assisted technologies in the writing process.
Gong et al. (Wed,) reported a other. Elevated serum EphA2 independently determined reduced eGFR (<60 mL/min/1.73m2), correlated with histological severity, and significantly decreased after steroid therapy in IgA nephropathy.